Type de la demande
BR Brevet
Sous-type de la demande
BR Brevet PCT
(10) Numéro et date d'enregistrement
015855 2013.03.29
Satut
175
(180) Date d'expiration
2028.04.10
(20) Numéro et date de dépot
OA 1/2009/000341 2008.04.10
(40) Numéro et date de publication
(86) PCT Numéro et date de dépoôt
(87) PCT Numéro et date de publication
(85) Date d'entrée en phase Nationale
(30) Détails de la priorité
US 60/922,732
2007.04.10
(71/73) Déposant
(FR) THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND : 1430 Tulane Avenue
(72) Inventeur
(FR) BAUSCH, Daniel, G. : 425 Arabella Street
(FR) BRANCO, Luis, M. : 310 Prettyman Drive, No. 7310
(FR) CASHMAN, Kathleen, A. : 603 Greysands Lane
(FR) FAIR, Joseph, N. : 1111 Weverton Rd.,
(FR) GARRY, Robert, F. : 2114 Pine Street,
(FR) GESKE, F., Jon : 17490 E. 104th Place
(FR) GUTTIERI, Mary, C. : 3634 Islington Street
(FR) ILLICK, Megan, M. : 2445, Lyttonsville Road, No. 1108
(FR) KULAKOSKY, Peter, C. : 510 Brockenbraugh Court
(FR) MATSCHINER, Alexander : 11840 Farmland Drive
(FR) SAMPEY, Darryl, B. : 171 South Columbus Avenue,
(FR) WILSON, Russell, B. : 146 Wisteria Lane
(74) Nom du représentant
(FR) SCP NICO HALLE & Co. LAW FIRM : ADRESSE A COMPLETER
(54) intituler
(FR) Soluble and membrane-anchored forms of lassa virus subunit proteins.
(57) Abrégé
(FR) The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.
(58) Citations